Beta Drugs Ltd (BETA) — shareholding pattern, promoter holding, financials and share price
About Beta Drugs Ltd (BETA)
Beta Drugs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BETA and on the BSE under scrip code 535022. Its ISIN is INE351Y01019.
Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets. [1]
Beta Drugs Limited is primarily engaged in manufacturing and marketing oncology drug products, catering to both domestic and international markets.
The company experienced a 13% revenue growth year-over-year, with notable expansions into 46+ countries, showcasing its extensive global reach and market acceptance.
Listed peers in Pharmaceuticals: Solara Active Pharma Sciences Ltd, Kwality Pharmaceuticals Ltd, Sai Parenterals Ltd, Indoco Remedies Ltd, Venus Remedies Ltd, Ind-Swift Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹2,366.8 a share on 10 Jul 2026, Beta Drugs Ltd (BETA) was valued at a price-to-earnings ratio of 61.8x against an industry P/E of 36.41x and a price-to-book of 12.17x on a book value of ₹194.43 per share as of Mar 2025. Solomo computes return on equity of 19.7% and return on capital employed of 20.08% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Mar 2026.
- P/E
- 61.8x
- Industry P/E
- 36.41x
- P/B
- 12.17x
- EPS (TTM)
- ₹38.3
- Book value / share
- ₹194.43
- ROE
- 19.7%
- ROCE
- 20.08%
- ROA
- 8.9%
- Debt / equity
- 0.67x
- Dividend yield
- 0%
- EBITDA margin
- 22.57%
- 52-week range
- ₹990.1 – ₹2,395
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Beta Drugs Ltd (BETA) reported revenue of ₹385 crore, net profit of ₹41 crore and earnings per share of ₹40.92. That compares with revenue of ₹362 crore and net profit of ₹42 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹93.96 crore and net profit ₹9.05 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 184 | 227 | 296 | 362 | 385 |
| Net profit (₹ cr) | 25 | 31 | 36 | 42 | 41 |
| EPS (₹) | 24.58 | 30.42 | 36.08 | 42.02 | 40.92 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 27.51% | 20.82% | 22.54% |
| Profit growth | 16.80% | 2.70% | 16.41% |
| Stock price CAGR | 44% | 47% | 35% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 59.1% of Beta Drugs Ltd (BETA) (down 5.53 pp QoQ). Market capitalisation was ₹2,399 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2018.
Largest disclosed public shareholders in Jun 2026: Suryavanshi Commotrade Private Limited 6.13%, Ashish Kacholia 4.91%, Healthquad Trust II 4.09%, Inti Capital Vcc - Inti Capital I 1.91%, Airavat Capital Trust - Airavat Capital Trust Ii 1.6%, Bsas Infotech Limited . 1.2%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 59.1% | - | - | - | - |
| Mar 2026 | 64.63% | - | - | - | - |
| Dec 2025 | 64.9% | - | - | - | - |
| Sep 2025 | 66.73% | - | - | - | - |
| Jun 2025 | 66.73% | - | - | - | - |
| Mar 2025 | 66.73% | - | - | - | - |
| Dec 2024 | 66.73% | - | - | - | - |
| Sep 2024 | 66.73% | - | - | - | - |